Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023

DelveInsight
70 Pages - DELVE14524
$2,750.00

DelveInsight’s “Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023-Global” Report provides an overview of the disease and the historical and forecasted epidemiological data for the Cytomegalovirus (CMV) Infection for Global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for the time period 2013-2023.
The report considers the transplant patients, HIV patients and Infants under high risk for CMV infections and epidemiology forecast for these high risk categories have also been taken into consideration. Of The 7 Major Markets, U.S. has the highest number of CMV Prevalent cases and Spain has the least number of CMV Prevalent cases. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
• Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis and disease management.
• Identifying patient populations in the global Cytomegalovirus (CMV) Infection market
• The Report covers the detailed historical and forecasted epidemiological data covering global from 2013-2023.

'

Cytomegalovirus Infections
Disease Overview
Symptoms of cytomegalovirus (CMV) Infection
Etiology
Risk Factors
Pathogenesis of human cytomegalovirus
Pathophysiology of cytomegalovirus infection
Diagnosis
Epidemiology and Patient Population
GLOBAL
Global CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Global CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
United States
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Europe
Italy
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Spain
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
United Kingdom
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Germany
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
France
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Japan
Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2016-2023)
CMV Patients among Transplants: Historical Data (2013-2015)
CMV Patients among Transplants: Forecasted Data (2016-2023)
Infants Patients at High Risk of CMV: Historical Data (2013-2015)
Infants Patients at High Risk of CMV: Forecasted Data (2016-2023)
HIV Patients at High Risk of CMV: Historical Data (2013-2015)
HIV Patients at High Risk of CMV: Forecasted Data (2016-2023)
Unmet Medical Needs
Assumptions and Rationale
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases: Foreacasted Data (2017-2023)
Table 3: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Historical Data (2013-2015)
Table 4: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Foreacasted Data (2017-2023)
Table 5: CMV Patients among Transplants in United States: Historical Data (2013-2015)
Table 6: CMV Patients among Transplants in United States: Foreacasted Data (2017-2023)
Table 7: Infants Patients at High Risk of CMV in United States: Historical Data (2013-2015)
Table 8: Infants Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
Table 9: HIV Patients at High Risk of CMV in United States: Historical Data (2013-2015)
Table 10: HIV Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
Table 11: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Historical Data (2013-2015)
Table 12: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Foreacasted Data (2017-2023)
Table 13: CMV Patients among Transplants in Italy: Historical Data (2013-2015)
Table 14: CMV Patients among Transplants in Italy: Foreacasted Data (2017-2023)
Table 15: Infants Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Table 16: Infants Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Table 17: HIV Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Table 18: HIV Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Table 19: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Historical Data (2013-2015)
Table 20: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Foreacasted Data (2017-2023)
Table 21: CMV Patients among Transplants in Spain: Historical Data (2013-2015)
Table 22: CMV Patients among Transplants in Spain: Foreacasted Data (2017-2023)
Table 23: Infants Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Table 24: Infants Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Table 25: HIV Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Table 26: HIV Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Table 27: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Historical Data (2013-2015)
Table 28: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Foreacasted Data (2017-2023)
Table 29: CMV Patients among Transplants in United Kingdom: Historical Data (2013-2015)
Table 30: CMV Patients among Transplants in United Kingdom: Foreacasted Data (2017-2023)
Table 31: Infants Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Table 32: Infants Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Table 33: HIV Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Table 34: HIV Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Table 35: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Historical Data (2013-2015)
Table 36: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Foreacasted Data (2017-2023)
Table 37: CMV Patients among Transplants in Germany: Historical Data (2013-2015)
Table 38: CMV Patients among Transplants in Germany: Foreacasted Data (2017-2023)
Table 39: Infants Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Table 40: Infants Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Table 41: HIV Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Table 42: HIV Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Table 43: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Historical Data (2013-2015)
Table 44: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Foreacasted Data (2017-2023)
Table 45: CMV Patients among Transplants in France: Historical Data (2013-2015)
Table 46: CMV Patients among Transplants in France: Foreacasted Data (2017-2023)
Table 47: Infants Patients at High Risk of CMV in France: Historical Data (2013-2015)
Table 48: Infants Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
Table 49: HIV Patients at High Risk of CMV in France: Historical Data (2013-2015)
Table 50: HIV Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
Table 51: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Historical Data (2013-2015)
Table 52: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Foreacasted Data (2017-2023)
Table 53: CMV Patients among Transplants in Japan: Historical Data (2013-2015)
Table 54: CMV Patients among Transplants in Japan: Foreacasted Data (2017-2023)
Table 55: Infants Patients at High Risk of CMV in Japan: Historical Data (2013-2015)
Table 56: Infants Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)
Table 57: HIV Patients at High Risk of CMV in Japan: Historical Data (2013-2015)
Table 58: HIV Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)

Figure 1: Risk Factors CMV infection, 2017
Figure 2: Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2015)
Figure 3: Total CMV Prevalent, Diagnosed and Treatable Cases: Foreacasted Data (2017-2023)
Figure 4: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Historical Data (2013-2015)
Figure 5: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Foreacasted Data (2017-2023)
Figure 6: CMV Patients among Transplants in United States: Historical Data (2013-2015)
Figure 7: CMV Patients among Transplants in United States: Foreacasted Data (2017-2023)
Figure 8: Infants Patients at High Risk of CMV in United States: Historical Data (2013-2015)
Figure 9: Infants Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
Figure 10: HIV Patients at High Risk of CMV in United States: Historical Data (2013-2015)
Figure 11: HIV Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
Figure 12: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Historical Data (2013-2015)
Figure 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Foreacasted Data (2017-2023)
Figure 14: CMV Patients among Transplants in Italy: Historical Data (2013-2015)
Figure 15: CMV Patients among Transplants in Italy: Foreacasted Data (2017-2023)
Figure 16: Infants Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Figure 17: Infants Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Figure 18: HIV Patients at High Risk of CMV in Italy: Historical Data (2013-2015)
Figure 19: HIV Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
Figure 20: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Historical Data (2013-2015)
Figure 21: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Foreacasted Data (2017-2023)
Figure 22: CMV Patients among Transplants in Spain: Historical Data (2013-2015)
Figure 23: CMV Patients among Transplants in Spain: Foreacasted Data (2017-2023)
Figure 24: Infants Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Figure 25: Infants Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Figure 26: HIV Patients at High Risk of CMV in Spain: Historical Data (2013-2015)
Figure 27: HIV Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
Figure 28: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Historical Data (2013-2015)
Figure 29: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Foreacasted Data (2017-2023)
Figure 30: CMV Patients among Transplants in United Kingdom: Historical Data (2013-2015)
Figure 31: CMV Patients among Transplants in United Kingdom: Foreacasted Data (2017-2023)
Figure 32: Infants Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Figure 33: Infants Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Figure 34: HIV Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2015)
Figure 35: HIV Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
Figure 36: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Historical Data (2013-2015)
Figure 37: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Foreacasted Data (2017-2023)
Figure 38: CMV Patients among Transplants in Germany: Historical Data (2013-2015)
Figure 39: CMV Patients among Transplants in Germany: Foreacasted Data (2017-2023)
Figure 40: Infants Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Figure 41: Infants Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Figure 42: HIV Patients at High Risk of CMV in Germany: Historical Data (2013-2015)
Figure 43: HIV Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
Figure 44: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Historical Data (2013-2015)
Figure 45: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Foreacasted Data (2017-2023)
Figure 46: CMV Patients among Transplants in France: Historical Data (2013-2015)
Figure 47: CMV Patients among Transplants in France: Foreacasted Data (2017-2023)
Figure 48: Infants Patients at High Risk of CMV in France: Historical Data (2013-2015)
Figure 49: Infants Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
Figure 50: HIV Patients at High Risk of CMV in France: Historical Data (2013-2015)
Figure 51: HIV Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
Figure 52: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Historical Data (2013-2015)
Figure 53: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Foreacasted Data (2017-2023)
Figure 54: CMV Patients among Transplants in Japan: Historical Data (2013-2015)
Figure 55: CMV Patients among Transplants in Japan: Foreacasted Data (2017-2023)
Figure 56: Infants Patients at High Risk of CMV in Japan: Historical Data (2013-2015)
Figure 57: Infants Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)
Figure 58: HIV Patients at High Risk of CMV in Japan: Historical Data (2013-2015)
Figure 59: HIV Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)

$2,750.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports